Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes

Journal of Immunology

Volumn 192, Issue 7, 2014, Pages 3269-3279

  Holl, T Matt ^a   Yang, Guang ^a   Kuraoka, Masayuki ^a   Verkoczy, Laurent ^a,b   Alam, S Munir ^a,b   Moody, M Anthony ^b   Haynes, Barton F ^a,b   Kelsoe, Garnett ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B CELL CULTURE; B LYMPHOCYTE; BONE MARROW; CELL COMPARTMENTALIZATION; CELL LABELING; CELL MATURATION; CELL SPECIFICITY; CONTROLLED STUDY; GERMINAL CENTER; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; LYMPHOCYTE RECIRCULATION; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; SPLEEN; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODY FORMATION; ANTIGENS, VIRAL; B-LYMPHOCYTES; BONE MARROW CELLS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FLOW CYTOMETRY; GERMINAL CENTER; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; IMMUNE TOLERANCE; LYMPHOCYTES; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN BINDING; SPLEEN;

EID: 84897487213     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302829     Document Type: Article

References (85)

1. Tomaras, G. D., and B. F. Haynes. 2009. HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr. Opin. HIV AIDS 4: 373-379.
2. Wei, X., J. M. Decker, S. Wang, H. Hui, J. C. Kappes, X. Wu, J. F. Salazar-Gonzalez, M. G. Salazar, J. M. Kilby, M. S. Saag, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
3. Shen, X., R. J. Parks, D. C. Montefiori, J. L. Kirchherr, B. F. Keele, J. M. Decker, W. A. Blattner, F. Gao, K. J. Weinhold, C. B. Hicks, et al. 2009. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J. Virol. 83: 3617-3625.
4. Burton, D. R., R. C. Desrosiers, R. W. Doms, W. C. Koff, P. D. Kwong, J. P. Moore, G. J. Nabel, J. Sodroski, I. A. Wilson, and R. T. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5: 233-236.
5. Mascola, J. R., and B. F. Haynes. 2013. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254: 225-244.
6. Gauduin, M. C., P. W. Parren, R. Weir, C. F. Barbas, D. R. Burton, and R. A. Koup. 1997. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med. 3: 1389-1393.
7. Mascola, J. R., G. Stiegler, T. C. VanCott, H. Katinger, C. B. Carpenter, C. E. Hanson, H. Beary, D. Hayes, S. S. Frankel, D. L. Birx, and M. G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6: 207-210.
8. Baba, T. W., V. Liska, R. Hofmann-Lehmann, J. Vlasak, W. Xu, S. Ayehunie, L. A. Cavacini, M. R. Posner, H. Katinger, G. Stiegler, et al. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6: 200-206.
9. Hessell, A. J., E. G. Rakasz, D. M. Tehrani, M. Huber, K. L. Weisgrau, G. Landucci, D. N. Forthal, W. C. Koff, P. Poignard, D. I. Watkins, and D. R. Burton. 2010. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membraneproximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J. Virol. 84: 1302-1313.
10. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888.
11. Zwick, M. B., A. F. Labrijn, M. Wang, C. Spenlehauer, E. O. Saphire, J. M. Binley, J. P. Moore, G. Stiegler, H. Katinger, D. R. Burton, and P. W. Parren. 2001. Broadly neutralizing antibodies targeted to the membraneproximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75: 10892-10905.
12. Nelson, J. D., F. M. Brunel, R. Jensen, E. T. Crooks, R. M. Cardoso, M. Wang, A. Hessell, I. A. Wilson, J. M. Binley, P. E. Dawson, et al. 2007. An affinityenhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J. Virol. 81: 4033-4043.
13. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Rüker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67: 6642-6647.
14. Huang, J., G. Ofek, L. Laub, M. K. Louder, N. A. Doria-Rose, N. S. Longo, H. Imamichi, R. T. Bailer, B. Chakrabarti, S. K. Sharma, et al. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406-412.
15. Derby, N. R., Z. Kraft, E. Kan, E. T. Crooks, S. W. Barnett, I. K. Srivastava, J. M. Binley, and L. Stamatatos. 2006. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J. Virol. 80: 8745-8762.
16. Coëffier, E., J. M. Clńment, V. Cussac, N. Khodaei-Boorane, M. Jehanno, M. Rojas, A. Dridi, M. Latour, R. El Habib, F. Barrń- Sinoussi, et al. 2000. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 19: 684-693.
17. Eckhart, L., W. Raffelsberger, B. Ferko, A. Klima, M. Purtscher, H. Katinger, and F. Rüker. 1996. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J. Gen. Virol. 77: 2001-2008.
18. Haynes, B. F., J. Fleming, E. W. St Clair, H. Katinger, G. Stiegler, R. Kunert, J. Robinson, R. M. Scearce, K. Plonk, H. F. Staats, et al. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906-1908.
19. Haynes, B. F., M. A. Moody, L. Verkoczy, G. Kelsoe, and S. M. Alam. 2005. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum. Antibodies 14: 59-67.
20. Verkoczy, L., M. Diaz, T. M. Holl, Y. B. Ouyang, H. Bouton-Verville, S. M. Alam, H. X. Liao, G. Kelsoe, and B. F. Haynes. 2010. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc. Natl. Acad. Sci. USA 107: 181-186.
21. Verkoczy, L., Y. Chen, H. Bouton-Verville, J. Zhang, M. Diaz, J. Hutchinson, Y. B. Ouyang, S. M. Alam, T. M. Holl, K. K. Hwang, et al. 2011. Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH × VL knockin mice reveals multiple tolerance controls. J. Immunol. 187: 3785-3797.
22. Doyle-Cooper, C., K. E. Hudson, A. B. Cooper, T. Ota, P. Skog, P. E. Dawson, M. B. Zwick, W. R. Schief, D. R. Burton, and D. Nemazee. 2013. Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10. J. Immunol. 191: 3186-3191.
23. Chen, Y., J. Zhang, K. K. Hwang, H. Bouton-Verville, S. M. Xia, A. Newman, Y. B. Ouyang, B. F. Haynes, and L. Verkoczy. 2013. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. J. Immunol. 191: 1260-1275.
24. Nemazee, D. A., and K. Bürki. 1989. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 337: 562-566.
25. Erikson, J., M. Z. Radic, S. A. Camper, R. R. Hardy, C. Carmack, and M. Weigert. 1991. Expression of anti-DNA immunoglobulin transgenes in nonautoimmune mice. Nature 349: 331-334.
26. Goodnow, C. C., J. Crosbie, H. Jorgensen, R. A. Brink, and A. Basten. 1989. Induction of self-tolerance in mature peripheral B lymphocytes. Nature 342: 385-391.
27. Yang, G., T. M. Holl, Y. Liu, Y. Li, X. Lu, N. I. Nicely, T. B. Kepler, S. M. Alam, H. X. Liao, D. W. Cain, et al. 2013. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J. Exp. Med. 210: 241-256.
28. Wardemann, H., S. Yurasov, A. Schaefer, J. W. Young, E. Meffre, and M. C. Nussenzweig. 2003. Predominant autoantibody production by early human B cell precursors. Science 301: 1374-1377.
29. Wardemann, H., and M. C. Nussenzweig. 2007. B-cell self-tolerance in humans. Adv. Immunol. 95: 83-110.
30. Nemazee, D., and M. Weigert. 2000. Revising B cell receptors. J. Exp. Med. 191: 1813-1817.
31. Hartley, S. B., J. Crosbie, R. Brink, A. B. Kantor, A. Basten, and C. C. Goodnow. 1991. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 353: 765-769.
32. Tiegs, S. L., D. M. Russell, and D. Nemazee. 1993. Receptor editing in selfreactive bone marrow B cells. J. Exp. Med. 177: 1009-1020.
33. Gay, D., T. Saunders, S. Camper, and M. Weigert. 1993. Receptor editing: an approach by autoreactive B cells to escape tolerance. J. Exp. Med. 177: 999-1008.
34. Russell, D. M., Z. Dembić, G. Morahan, J. F. Miller, K. Bürki, and D. Nemazee. 1991. Peripheral deletion of self-reactive B cells. Nature 354: 308-311.
35. Hartley, S. B., M. P. Cooke, D. A. Fulcher, A. W. Harris, S. Cory, A. Basten, and C. C. Goodnow. 1993. Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell 72: 325-335.
36. Adams, E., A. Basten, and C. C. Goodnow. 1990. Intrinsic B-cell hyporesponsiveness accounts for self-tolerance in lysozyme/anti-lysozyme doubletransgenic mice. Proc. Natl. Acad. Sci. USA 87: 5687-5691.
37. Holl, T. M., B. F. Haynes, and G. Kelsoe. 2010. Stromal cell independent B cell development in vitro: generation and recovery of autoreactive clones. J. Immunol. Methods 354: 53-67.
38. Sandel, P. C., M. Gendelman, G. Kelsoe, and J. G. Monroe. 2001. Definition of a novel cellular constituent of the bone marrow that regulates the response of immature B cells to B cell antigen receptor engagement. J. Immunol. 166: 5935-5944.
39. Sandel, P. C., and J. G. Monroe. 1999. Negative selection of immature B cells by receptor editing or deletion is determined by site of antigen encounter. Immunity 10: 289-299.
40. Verkoczy, L., M. A. Moody, T. M. Holl, H. Bouton-Verville, R. M. Scearce, J. Hutchinson, S. M. Alam, G. Kelsoe, and B. F. Haynes. 2009. Functional, nonclonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region. PLoS ONE 4: e7215.
41. Hardy, R. R., and K. Hayakawa. 2001. B cell development pathways. Annu. Rev. Immunol. 19: 595-621.
42. Kuraoka, M., T. M. Holl, D. Liao, M. Womble, D. W. Cain, A. E. Reynolds, and G. Kelsoe. 2011. Activation-induced cytidine deaminase mediates central tolerance in B cells. Proc. Natl. Acad. Sci. USA 108: 11560-11565.
43. Ueda, Y., D. Liao, K. Yang, A. Patel, and G. Kelsoe. 2007. T-independent activation-induced cytidine deaminase expression, class-switch recombination, and antibody production by immature/transitional 1 B cells. J. Immunol. 178: 3593-3601.
44. Shefner, R., G. Kleiner, A. Turken, L. Papazian, and B. Diamond. 1991. A novel class of anti-DNA antibodies identified in BALB/c mice. J. Exp. Med. 173: 287-296.
45. Gray, E. S., M. A. Moody, C. K. Wibmer, X. Chen, D. Marshall, J. Amos, P. L. Moore, A. Foulger, J. S. Yu, B. Lambson, et al. 2011. Isolation of a monoclonal antibody that targets the a-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. J. Virol. 85: 7719-7729.
46. Morris, L., X. Chen, M. Alam, G. Tomaras, R. Zhang, D. J. Marshall, B. Chen, R. Parks, A. Foulger, F. Jaeger, et al. 2011. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS ONE 6: e23532.
47. Moody, M. A., N. L. Yates, J. D. Amos, M. S. Drinker, J. A. Eudailey, T. C. Gurley, D. J. Marshall, J. F. Whitesides, X. Chen, A. Foulger, et al. 2012. HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J. Virol. 86: 7496-7507.
48. Liao, H. X., M. Bonsignori, S. M. Alam, J. S. McLellan, G. D. Tomaras, M. A. Moody, D. M. Kozink, K. K. Hwang, X. Chen, C. Y. Tsao, et al. 2013. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38: 176-186.
49. Alam, S. M., R. M. Scearce, R. J. Parks, K. Plonk, S. G. Plonk, L. L. Sutherland, M. K. Gorny, S. Zolla-Pazner, S. Vanleeuwen, M. A. Moody, et al. 2008. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J. Virol. 82: 115-125.
50. Beger, E., B. Deocharan, M. Edelman, B. Erblich, Y. Gu, and C. Putterman. 2002. A peptide DNA surrogate accelerates autoimmune manifestations and nephritis in lupus-prone mice. J. Immunol. 168: 3617-3626.
51. Melchers, F., and A. R. Rolink. 2006. B cell tolerance: how to make it and how to break it. Curr. Top. Microbiol. Immunol. 305: 1-23.
52. Scheid, J. F., H. Mouquet, N. Feldhahn, M. S. Seaman, K. Velinzon, J. Pietzsch, R. G. Ott, R. M. Anthony, H. Zebroski, A. Hurley, et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458: 636-640.
53. Gilkeson, G. S., A. M. Pippen, and D. S. Pisetsky. 1995. Induction of crossreactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA. J. Clin. Invest. 95: 1398-1402.
54. Ferrantelli, F., and R. M. Ruprecht. 2002. Neutralizing antibodies against HIV: back in the major leagues? Curr. Opin. Immunol. 14: 495-502.
55. Jacob, J., G. Kelsoe, K. Rajewsky, and U. Weiss. 1991. Intraclonal generation of antibody mutants in germinal centres. Nature 354: 389-392.
56. Jacob, J., R. Kassir, and G. Kelsoe. 1991. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations. J. Exp. Med. 173: 1165-1175.
57. Rajewsky, K. 1996. Clonal selection and learning in the antibody system. Nature 381: 751-758.
58. Graham, B. S. 2002. Clinical trials of HIV vaccines. Annu. Rev. Med. 53: 207-221.
59. Letvin, N. L., D. H. Barouch, and D. C. Montefiori. 2002. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu. Rev. Immunol. 20: 73-99.
60. Pietzsch, J., J. F. Scheid, H. Mouquet, M. S. Seaman, C. C. Broder, and M. C. Nussenzweig. 2010. Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J. Virol. 84: 5032-5042.
61. Ofek, G., F. J. Guenaga, W. R. Schief, J. Skinner, D. Baker, R. Wyatt, and P. D. Kwong. 2010. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl. Acad. Sci. USA 107: 17880-17887.
62. Guenaga, J., P. Dosenovic, G. Ofek, D. Baker, W. R. Schief, P. D. Kwong, G. B. Karlsson Hedestam, and R. T. Wyatt. 2011. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS ONE 6: e16074.
63. McHeyzer-Williams, M. G., M. J. McLean, P. A. Lalor, and G. J. Nossal. 1993. Antigen-driven B cell differentiation in vivo. J. Exp. Med. 178: 295-307.
64. Lalor, P. A., G. J. Nossal, R. D. Sanderson, and M. G. McHeyzer-Williams. 1992. Functional and molecular characterization of single, (4-hydroxy-3- nitrophenyl)acetyl (NP)-specific, IgG1+ B cells from antibody-secreting and memory B cell pathways in the C57BL/6 immune response to NP. Eur. J. Immunol. 22: 3001-3011.
65. McHeyzer-Williams, M. G., G. J. Nossal, and P. A. Lalor. 1991. Molecular characterization of single memory B cells. Nature 350: 502-505.
66. Takemori, T., H. Tesch, M. Reth, and K. Rajewsky. 1982. The immune response against anti-idiotope antibodies. I. Induction of idiotope-bearing antibodies and analysis of the idiotope repertoire. Eur. J. Immunol. 12: 1040-1046.
67. Reth, M., T. Imanishi-Kari, and K. Rajewsky. 1979. Analysis of the repertoire of anti-(4-hydroxy-3-nitrophenyl)acetyl (NP) antibodies in C 57 BL/6 mice by cell fusion. II. Characterization of idiotopes by monoclonal anti-idiotope antibodies. Eur. J. Immunol. 9: 1004-1013.
68. Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94-96.
69. Newman, J., J. S. Rice, C. Wang, S. L. Harris, and B. Diamond. 2003. Identification of an antigen-specific B cell population. J. Immunol. Methods 272: 177-187.
70. Bonsignori, M., K. K. Hwang, X. Chen, C. Y. Tsao, L. Morris, E. Gray, D. J. Marshall, J. A. Crump, S. H. Kapiga, N. E. Sam, et al. 2011. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85: 9998-10009.
71. Liao, H. X., R. Lynch, T. Zhou, F. Gao, S. M. Alam, S. D. Boyd, A. Z. Fire, K. M. Roskin, C. A. Schramm, Z. Zhang, et al; NISC Comparative Sequencing Program. 2013. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496: 469-476.
72. Yurasov, S., H. Wardemann, J. Hammersen, M. Tsuiji, E. Meffre, V. Pascual, and M. C. Nussenzweig. 2005. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 201: 703-711.
73. Samuels, J., Y. S. Ng, C. Coupillaud, D. Paget, and E. Meffre. 2005. Impaired early B cell tolerance in patients with rheumatoid arthritis. J. Exp. Med. 201: 1659-1667.
74. Lopes-Carvalho, T., and J. F. Kearney. 2004. Development and selection of marginal zone B cells. Immunol. Rev. 197: 192-205.
75. Takahashi, S., S. Futatsugi-Yumikura, A. Fukuoka, T. Yoshimoto, K. Nakanishi, and S. Yonehara. 2013. Fas deficiency in mice with the Balb/c background induces blepharitis with allergic inflammation and hyper-IgE production in conjunction with severe autoimmune disease. Int. Immunol. 25: 287-293.
76. Gorham, J. D., J. T. Lin, J. L. Sung, L. A. Rudner, and M. A. French. 2001. Genetic regulation of autoimmune disease: BALB/c background TGF-b1-deficient mice develop necroinflammatory IFN-γ-dependent hepatitis. J. Immunol. 166: 6413-6422.
77. Löhler, J., B. Sadlack, H. Schorle, G. Klebb, H. Haber, and I. Horak. 1996. [Generalized autoimmune diseases in BALB/c mice with a genetically dependent interleukin-2 deficiency]. Verh. Dtsch. Ges. Pathol. 80: 293-296.
78. Baddack, U., S. Hartmann, H. Bang, J. Grobe, C. Loddenkemper, M. Lipp, and G. Müller. 2013. A chronic model of arthritis supported by a strain-specific periarticular lymph node in BALB/c mice. Nat. Commun. 4: 1644.
79. Verkoczy, L., G. Kelsoe, M. A. Moody, and B. F. Haynes. 2011. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr. Opin. Immunol. 23: 383-390.
80. Han, S., B. Zheng, J. Dal Porto, and G. Kelsoe. 1995. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. IV. Affinitydependent, antigen-driven B cell apoptosis in germinal centers as a mechanism for maintaining self-tolerance. J. Exp. Med. 182: 1635-1644.
81. Tiller, T., M. Tsuiji, S. Yurasov, K. Velinzon, M. C. Nussenzweig, and H. Wardemann. 2007. Autoreactivity in human IgG+ memory B cells. Immunity 26: 205-213.
82. Haynes, B. F., G. Kelsoe, S. C. Harrison, and T. B. Kepler. 2012. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30: 423-433.
83. Bonsignori, M., K. Wiehe, S. K. Grimm, R. Lynch, G. Yang, D. M. Kozink, F. Perrin, A. Cooper, K. K. Hwang, X. Chen, et al. 2014. An autoreactive broadly neutralizing CD4 binding site antibody from an HIV-1 controller with systemic lupus erythematosus. J. Clin. Invest. In press.
84. Levine, M. H., A. M. Haberman, D. B. Sant'Angelo, L. G. Hannum, M. P. Cancro, C. A. Janeway, Jr., and M. J. Shlomchik. 2000. A B-cell receptorspecific selection step governs immature to mature B cell differentiation. Proc. Natl. Acad. Sci. USA 97: 2743-2748.
85. Hsu, B. L., S. M. Harless, R. C. Lindsley, D. M. Hilbert, and M. P. Cancro. 2002. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J. Immunol. 168: 5993-5996.